Neurocrine Biosciences Inc (NBIX) stock
NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/306% below fair value
$165.92+0.61 (+0.37%)
Close on Nov 17, 2026Market cap $16.87BP/E 24.3Yield –
Neurocrine Biosciences EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Neurocrine Biosciences's EV/EBITDA was 21.8× on Nov 11, 2026, against 25.5× a year earlier. Over the last 5 years it ranged from 16.9× to 156.9×, with a median of 28.1×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 21.8× | −1.9 |
| 2025 | Dec 31, 2025 | 23.7× | +1.9 |
| 2024 | Dec 31, 2024 | 21.7× | −36.3 |
| 2023 | Dec 29, 2023 | 58.1× | −39.6 |
| 2022 | Dec 30, 2022 | 97.7× | +63.0 |
| 2021 | Dec 31, 2021 | 34.7× | −22.5 |
| 2020 | Dec 31, 2020 | 57.2× | −120.5 |
| 2019 | Dec 31, 2019 | 177.7× | −29.3 |
| 2018 | Dec 31, 2018 | 207.0× | −75.1 |
| 2013 | Apr 30, 2013 | 282.1× | +271.2 |
| 2012 | Oct 31, 2012 | 10.9× | +0.4 |
| 2011 | Dec 30, 2011 | 10.5× | – |
See a number that looks wrong?